# A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Finding useful health information on the Internet can be difficult, but we’re here to help. This page gathers quality information from trusted sources. You can learn more about the disease, visit handpicked websites, and find resources to help you in your daily life. Need more information? Click the menu on the left to find more!

 

Idiopathic pulmonary fibrosis

Familial pulmonary fibrosis
Get Update

Clinical Trials

This information is provided by ClinicalTrials.gov

Search Clinical Trials
Displaying 61-70 of 364 results.
Investigating Trends in Quality of Life in Patients With Idiopathic Pulmonary Fibrosis (IPF) Under Treatment With Nintedanib
Status: Recruiting
Last Changed: Oct 23, 2020
First Received: Oct 18, 2018
Disease(s): Idiopathic Pulmonary Fibrosis
Intervention(s): Nintedanib
Locations: University General Hospital of Evros, Alexandroupoli, Greece
Gen. Hosp. of Chest Diseases "Sotiria", Univ. Resp. Med., Athens, Greece
University General Hospital Attikon, Athens, Greece
University Hospital of Heraklion, University Pulmonology Cl, Heraklion, Greece
General Hospital of Kerkyra, Kerkyra, Greece
... and 4 other locations.
First Time in Human (FTIH) Study of GSK3008348 in Healthy Volunteers and Idiopathic Pulmonary Fibrosis Patients
Status: Completed
Last Changed: May 01, 2017
First Received: Nov 23, 2015
Disease(s): Idiopathic Pulmonary Fibrosis
Intervention(s): GSK3008348 Nebuliser solution, Placebo Nebuliser solution, GSK26346763: ([18F]-FBA-A20FMDV2) IV infusion
Locations: GSK Investigational Site, London, United Kingdom
An Efficacy and Safety Study of BG00011 in Participants With Idiopathic Pulmonary Fibrosis
Status: Terminated
Last Changed: Oct 01, 2020
First Received: Jun 29, 2018
Disease(s): Idiopathic Pulmonary Fibrosis
Intervention(s): BG00011, Placebo
Locations: Research Site, Birmingham, Alabama, United States
Research Site, Phoenix, Arizona, United States
Research Site, Phoenix, Arizona, United States
Research Site, Los Angeles, California, United States
Research Site, New Haven, Connecticut, United States
... and 86 other locations.
A Clinical Study to Test How Effective and Safe GLPG1205 is for Patients With Idiopathic Pulmonary Fibrosis (IPF)
Status: Completed
Last Changed: Sep 11, 2020
First Received: Oct 31, 2018
Disease(s): Idiopathic Pulmonary Fibrosis
Intervention(s): GLPG1205, Placebo
Locations: Specialized Hospital for Active Treatment Pleven, Pleven, Bulgaria
SHATPPD Dr. Dimitar Gramatikov, Ruse Ltd., Ruse, Bulgaria
Acibadem City Clinic Tokuda Hospital, EAD, Sofia, Bulgaria
Klinicki Bolnicki Centar Rijeka - Susak, Rijeka, Croatia
Klinička Bolnica Dubrava, Zagreb, Croatia
... and 32 other locations.
Characteristics and Health Related Quality of Life in Idiopathic Pulmonary Fibrosis
Status: Unknown status
Last Changed: May 31, 2017
First Received: May 31, 2017
Disease(s): Idiopathic Pulmonary Fibrosis
Intervention(s): high resolution computed tomography
Beneficial Effects of Pulmonary Rehabilitation for Idiopathic Pulmonary Fibrosis
Status: Completed
Last Changed: Oct 22, 2020
First Received: Apr 20, 2010
Disease(s): Idiopathic Pulmonary Fibrosis
Intervention(s): Standard pulmonary rehabilitation program
Locations: National Jewish Health, Denver, Colorado, United States
Correlating Outcomes With Biochemical Markers to Estimate Time-progression in Idiopathic Pulmonary Fibrosis (IPF)
Status: Completed
Last Changed: Oct 17, 2012
First Received: Feb 19, 2010
Disease(s): Idiopathic Pulmonary Fibrosis
Locations: University of California, Los Angeles, Los Angeles, California, United States
University of California, San Francisco, San Francisco, California, United States
National Jewish Medical and Research Center, Denver, Colorado, United States
University of Chicago, Chicago, Illinois, United States
University of Michigan, Ann Arbor, Michigan, United States
... and 5 other locations.
A Clinical Study to Test How Effective and Safe GLPG1690 is for Subjects With Idiopathic Pulmonary Fibrosis (IPF) When Used Together With Standard of Care
Status: Recruiting
Last Changed: Jul 14, 2020
First Received: Nov 07, 2018
Disease(s): Idiopathic Pulmonary Fibrosis
Intervention(s): GLPG1690, Placebo
Locations: University of Alabama at Birmingham, Birmingham, Alabama, United States
Arizona Pulmonary Specialists, Phoenix, Arizona, United States
University of Arizona College of Medicine, Tucson, Arizona, United States
Keck School of Medicine of USC, Los Angeles, California, United States
Cedars Sinai Medical Center, Los Angeles, California, United States
... and 128 other locations.
A Clinical Study to Test How Effective and Safe GLPG1690 is for Subjects With Idiopathic Pulmonary Fibrosis (IPF) When Used Together With Standard of Care
Status: Recruiting
Last Changed: Sep 07, 2020
First Received: Oct 18, 2018
Disease(s): Idiopathic Pulmonary Fibrosis
Intervention(s): GLPG1690, Placebo
Locations: Pulmonary Associates, Phoenix, Arizona, United States
Mayo Clinic Arizona - PPDS, Scottsdale, Arizona, United States
David Geffen School of Medicine at UCLA, Los Angeles, California, United States
Respire Research, Palm Springs, California, United States
University of California San Diego, San Diego, California, United States
... and 110 other locations.
Evaluate the Safety and Efficacy of FG-3019 (Pamrevlumab) in Participants With Idiopathic Pulmonary Fibrosis (IPF)
Status: Completed
Last Changed: Sep 04, 2020
First Received: Jul 01, 2013
Disease(s): Idiopathic Pulmonary Fibrosis
Intervention(s): Pamrevlumab, Placebo, Sub-Study: Pirfenidone, Sub-Study: Nintedanib
Locations: The Kirklin Clinic, Birmingham, Alabama, United States
David Geffen School of Medicine at UCLA, Los Angeles, California, United States
UC Davis Medical Center, Sacramento, California, United States
National Jewish Health, Denver, Colorado, United States
Yale University, New Haven, Connecticut, United States
... and 38 other locations.